Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 4 · 66.7%High 0 · 0%

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

All‐cause mortality · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in mortality compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.94 [0.64, 1.38]
3 studies · 1440 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Pulmonary embolism · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis probably leads to lower pulmonary embolism compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.48 [0.24, 0.98]
3 studies · 1440 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Symptomatic DVT · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in symptomatic deep vein thrombosis compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 0.61 [0.31, 1.21]
3 studies · 1440 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Major bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in major bleeding compared with no prophylaxis (moderate certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 1.65 [0.72, 3.8]
3 studies · 1440 participants
Moderate

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Minor bleeding · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

Direct oral anticoagulant (DOAC) prophylaxis showed no clear difference in minor bleeding compared with no prophylaxis (low certainty).

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
RR 3.58 [0.55, 23.44]
3 studies · 1440 participants
Low

Direct oral anticoagulant (DOAC) prophylaxis vs no prophylaxis

Outcome: · ambulatory people with cancer without venous thromboembolism receiving systemic therapy

The review found no eligible studies for this question.

1 finding from 1 review

Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found